Mammen Mathai 4
4 · JOHNSON & JOHNSON · Filed Feb 17, 2022
Insider Transaction Report
Form 4
Mammen Mathai
EVP, Pharm, R&D
Transactions
- Tax Payment
Common Stock
2022-02-15$165.89/sh−3,366$558,386→ 41,934 total - Exercise/Conversion
Common Stock
2022-02-15+7,740→ 45,300 total - Award
Employee Stock Options (Right to Buy)
2022-02-14$165.89/sh+38,736$6,425,915→ 38,736 totalFrom: 2025-02-14Exp: 2032-02-14→ Common Stock (38,736 underlying) - Award
Restricted Share Units
2022-02-14+3,922→ 3,922 totalFrom: 2025-02-14→ Common Stock (3,922 underlying) - Exercise/Conversion
Performance Share Units
2022-02-15−7,740→ 737 totalFrom: 2022-02-11→ Common Stock (7,740 underlying)
Footnotes (5)
- [F1]Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.
- [F2]Shares withheld for payment of taxes upon vesting of Performance Share Units.
- [F3]Awarded under Issuer's Long-Term Incentive Plan.
- [F4]Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant.
- [F5]Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019. A portion of these Performance Share Units have been forfeited.